Targeted temperature management after out-of-hospital cardiac arrest: certainties and uncertainties
Critical Care volume 18, Article number: 459 (2014)
Targeted temperature management was adopted as part of the treatment of unconscious survivors of out-of-hospital cardiac arrest following the publication of two landmark studies , which concluded that mild induced hypothermia (32°C to 34°C) improved survival and neurological outcome, substantiating the neuroprotective effect of mild hypothermia described in experimental animal data . Subsequently, this therapy was recommended by international guidelines , and became a standard of care. Although both trials , had exclusion criteria limiting generalizability, mild induced hypothermia was applied to the wider cardiac arrest population.
Until recently , despite uncertainties over what represents the optimal target population, temperature, duration of therapy, or rate of rewarming , no large randomized clinical trials (RCTs) had been conducted since 2003. A systematic review and meta-analysis performed by using the Grading of Recommendations Assessment, Development, and Evaluation system  and trial sequential analysis  concluded that the existing quality of evidence was low and that firm evidence in support of induced hypothermia was lacking .
To further investigate targeted temperature management, the Target Temperature Management (TTM) after out-of-hospital cardiac arrest trial group was established. As mild induced hypothermia had become ingrained in clinical practice, it was considered infeasible to compare 32°C to 34°C with no temperature control, as failing to control fever would have been unacceptable to many clinicians. The primary objective of the TTM trial  was to compare 33°C with 36°C in unconscious survivors of out-of-hospital cardiac arrest for survival for a minimum follow-up of 6 months. A temperature of 36°C was chosen as registry data showed that 36°C was the median temperature of out-of-hospital cardiac arrest patients arriving at the hospital. Furthermore, it was unlikely that, if feedback-controlled cooling devices were used, the temperature in the 36°C group would stray into the febrile range.
The TTM trial sought to be pragmatic, reflecting current clinical practice  of applying mild induced hypothermia to the entire out-of-hospital cardiac arrest population. Arrests of a presumed cardiac cause of all rhythms, including witnessed asystole, were included, as neuroprotection should not depend on initial rhythm. The trial protocol and analysis plan were published in advance and attempted to address possible deficiencies of previous trials ,. These included the following: a sample size twice as large as all previous RCTs combined (939 versus 478) adequately powered to detect or reject differences in survival, documentation of coma level at randomization, avoidance of hyperthermia both during and after completion of target temperature management in unconscious patients, standardized neurological assessment/prognostication, and guidance for withdrawal of treatment (adverse events, including infections, bleeding, electrolyte disturbances, seizures, and arrhythmias, were also recorded); a blinded neurological follow-up , extending beyond crude scales (Cerebral Performance Category and modified Rankin Scale), including tests on quality of life and cognitive function assessing both survivors and relatives in a face-to-face visit in the majority; and a bio-bank of approximately 20,000 blood samples to investigate the role of biomarkers.
The results of the TTM trial were unequivocal, demonstrating no difference in survival or the secondary outcome of combined survival and neurological outcome . An important design feature of the TTM trial, distinguishing it from earlier trials, was the approach to prognostication and withdrawal of care in patients remaining unconscious ,. Prognostication was delayed for 108 hours (unless specific withdrawal criteria were met) and performed by a clinician who was blinded to the intervention and who then recommended withdrawal, continuation, or no further escalation of care.
The robust design of the TTM trial has been recognized by a number of commentators ,, including an author of one of the landmark trials . However, others have questioned the validity of the study, raising concerns over the rate of rewarming, temperature separation and swings, and recruitment rates . It has been argued that the rate of rewarming was rapid, abrogating the benefits of cooling to 33°C . The optimal rate of rewarming remains unknown  but was undertaken at a maximum speed of 0.5°C per hour in keeping with current guidelines . The actual rewarming rate in the TTM trial was 0.36 ± 0.13°C per hour, which seems comparable to the rate in the Hypothermia after Cardiac Arrest trial , and the two temperature arms were clearly well controlled and separated (Figure 1). The TTM trial aimed to reflect current clinical practice, including as large a population as possible to make the results applicable to use by clinicians. On the basis of registries, 80% of patients meeting inclusion criteria in the TTM trial would be eligible for random assignment after exclusion criteria were considered . The 66% screening to inclusion (and 76% random assignment of patients meeting inclusion criteria) represents a considerable effort by participating sites. Although the study ran more than 26 months, it was not until 9 months that 50% of sites were open to recruitment. The median number of patients randomly assigned per site was 21, and sites above the median recruited 80% of all patients.
In this trial (the largest one to date), there was no difference in outcomes between unconscious survivors of out-of-hospital cardiac arrest treated at 33°C or 36°C, giving clinicians the option of choosing either temperature management strategy, but the least invasive strategy is compelling . The most interesting aspect of the TTM trial may be that it indicates substantial knowledge gaps in post-cardiac arrest fever and temperature management. The optimal temperature, duration of temperature management, and target population remain to be defined.
Randomized clinical trial
Target temperature management
Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002, 346: 549-556. 10.1056/NEJMoa012689.
Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002, 346: 557-563. 10.1056/NEJMoa003289.
Marion DW, Leonov Y, Ginsberg M, Katz LM, Kochanek PM, Lechleuthner A, Nemoto EM, Obrist W, Safar P, Sterz F, Tisherman SA, White RJ, Xiao F, Zar H: Resuscitative hypothermia. Crit Care Med. 1996, 24 (2 suppl): S81-S89.
Nolan JP, Morley PT, Hoek TL, Hickey RW: Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life support Task Force of the International Liaison committee on Resuscitation. Resuscitation. 2003, 57: 231-235. 10.1016/S0300-9572(03)00184-9.
Nolan JP, Soar J, Zideman DA, Biarent D, Bossaert LL, Deakin C, Koster RW, Wyllie J, Böttiger B: European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation. 2010, 81: 1219-1276. 10.1016/j.resuscitation.2010.08.021.
Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, et al: Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013, 369: 2197-2206. 10.1056/NEJMoa1310519.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW, Zaza S: Grading quality of evidence and strength of recommendations. BMJ. 2004, 328: 1490-10.1136/bmj.328.7454.1490.
Brok J, Thorlund K, Gluud C, Wetterslev J: Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008, 61: 763-769. 10.1016/j.jclinepi.2007.10.007.
Nielsen N, Friberg H, Gluud C, Herlitz J, Wetterslev J: Hypothermia after cardiac arrest should be further evaluated - a systematic review of randomised trials with meta-analysis and trial sequential analysis. Int J Cardiol. 2011, 151: 333-341. 10.1016/j.ijcard.2010.06.008.
Nielsen N, Wetterslev J, Al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G, Brunetti I, Cranshaw J, Cronberg T, Edqvist K, Erlinge D, Gasche Y, Glover G, Hassager C, Horn J, Hovdenes J, Johnsson J, Kjaergaard J, Kuiper M, Langørgen J, Macken L, Martinell L, Martner P, Pellis T, Pelosi P, Petersen P, Persson S, Rundgren M, Saxena M, Svensson R, et al: Target Temperature Management after out-of-hospital cardiac arrest - a randomized, parallel-group, assessor-blinded clinical trial - rationale and design. Am Heart J. 2012, 163: 541-548. 10.1016/j.ahj.2012.01.013.
Nielsen N, Winkel P, Cronberg T, Erlinge D, Friberg H, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Wetterslev J: Detailed statistical analysis plan for the target temperature management after out-of-hospital cardiac arrest trial. Trials. 2013, 14: 300-10.1186/1745-6215-14-300.
Lilja G, Nielsen N, Friberg H, Horn J, Kjaergaard J, Pellis T, Rundgren M, Wetterslev J, Wise MP, Nilsson F, Cronberg T: Cognitive function after cardiac arrest and temperature management; rationale and description of a sub-study in the Target Temperature Management trial. BMC Cardiovasc Disord. 2013, 13: 85-10.1186/1471-2261-13-85.
Bernard S: Inducing hypothermia after out of hospital cardiac arrest. BMJ. 2014, 348: g2735-10.1136/bmj.g2735.
Rittenberger JC, Callaway CW: Temperature management and modern post-cardiac arrest care. N Engl J Med. 2013, 369: 2262-2263. 10.1056/NEJMe1312700.
Polderman KH, Varon J: We should not abandon therapeutic cooling after cardiac arrest. Crit Care. 2014, 18: 130-10.1186/cc13817.
Nielsen N, Hovdenes J, Nilsson F, Rubertsson S, Stammet P, Sunde K, Valsson F, Wanscher M, Friberg H: Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2009, 53: 926-934. 10.1111/j.1399-6576.2009.02021.x.
MPW and NN have received speaker fees from BARD (Murray Hill, New Jersey, USA). The other authors declare that they have no competing interests.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Wise, M.P., Horn, J., Åneman, A. et al. Targeted temperature management after out-of-hospital cardiac arrest: certainties and uncertainties. Crit Care 18, 459 (2014). https://doi.org/10.1186/s13054-014-0459-3